Peer-reviewed veterinary case report
Safety and effectiveness of HisAK70 vaccine against Leishmania in dogs
By Martínez-Rodrigo, Abel et al.·Published in Comparative immunology, microbiology and infectious diseases·2019·Department of Animal Health, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection.
- Species:
- dog
Plain-English summary
A group of dogs was tested with a new vaccine called HisAK70 to see if it could help protect them against Leishmania infantum, a parasite that causes serious illness. After receiving the vaccine, the dogs showed a significant decrease in the infection levels, with reductions of up to 54% after 30 days and nearly 67% after 100 days compared to dogs that did not receive the vaccine. The vaccine was found to be safe and showed promise in helping dogs fight off this infection. This could be an encouraging option for preventing Leishmania in dogs.
People also search for: dog leishmaniasis vaccine · HisAK70 vaccine for dogs · Leishmania infection in dogs · dog vaccine safety · canine leishmaniasis treatment
Abstract
HisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of peripheral blood-derived dendritic cells (DCs) pulsed with the same pathoantigen and CpG ODN as an adjuvant) to explore the antileishmanial activity in an ex vivo canine co-culture system in the presence of Leishmania infantum parasites. In the canine model, the heterologous HisAK70 vaccine could decrease the infection index in the DC-T cell co-culture system by up to 54% after 30 days and reach almost 67% after 100 days post-immunization, respectively, compared to those obtained in the control group of dogs. The observed security and potential to fight ex vivo L. infantum infection highlight a HisAK70 heterologous immunization strategy as a promising alternative to evaluate its effectiveness against canine VL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31300103/